Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

View Full Paper
Ask AI
Bookmark
Share

Authors

UTUrbain Tauveron-JalenquesMCMartin CarréUTUgo Thévenet

Discussion

Loading...

Member takes

Overview

Retrospective study reports improved response rate in TP53 AML patients treated with azacitidine and venetoclax, suggesting prognostic factors impact outcomes.

Key Points

  • This study evaluates the outcomes of patients with TP53-mutant acute myeloid leukemia (AML) treated with azacitidine and venetoclax chemotherapy.
  • Retrospective analysis of TP53mut AML patients from the VENAURA registry
  • Data collection from 10 centers in Auvergne Rhône Alpes region
  • Evaluation of factors influencing treatment outcomes including mutation load and performance status.
  • Response rate (CRc) of 54% observed in treated patients
  • Median overall survival was 7.4 months with variations based on allelic status
  • Performance status and leucocyte count were predictive of treatment outcome.

Cite This Study

Tauveron-Jalenques et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da7ehttps://doi.org/10.1182/blood-2025-3442
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of TP53-mutated acute myeloid leukemia at a single institution.2026
  2. 2TP53-mutated AML and treatment outcomes in the era of hypomethylating agent/venetoclax therapy2025
  3. 3Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion2025 · 1 citations
  4. 4Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study2025 · 1 citations
  5. 5Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study2025 · 1 citations